Multidrug resistance-associated protein 2 (MRP2) mediated transport of oxaliplatin-derived platinum in membrane vesicles

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Myint, Khine ^a   Li, Yan ^c   Paxton, James ^a,b   McKeage, Mark ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5(6) CARBOXY 2,'7' DICHLOROFLUORESCEIN; ADENOSINE TRIPHOSPHATE; CHLORIDE ION; DICHLOROFLUORESCEIN; GLUTATHIONE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MYRICETIN; OXALIPLATIN; UNCLASSIFIED DRUG; VERLUKAST; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PLATINUM; PLATINUM COMPLEX;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CHROMATOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG STABILITY; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MEMBRANE TRANSPORT; MEMBRANE VESICLE; NONHUMAN; ULTRAVIOLET RADIATION; ANIMAL; CELL MEMBRANE; DRUG EFFECTS; METABOLISM; SF9 CELL LINE; SPODOPTERA;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELL MEMBRANE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPLATINUM COMPOUNDS; PLATINUM; SF9 CELLS; SPODOPTERA;

EID: 84940094595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130727     Document Type: Article

References (51)

1. Stein A, Arnold D. Oxaliplatin: a review of approved uses. Expert Opinion on Pharmacotherapy. 2012; 13(1):125-37. doi: 10.1517/14656566.2012.643870 PMID: WOS:000297854000011.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. Epub 2011/05/13. doi: 10.1056/NEJMoa1011923 PMID: 21561347.
3. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22(11):2084-91. Epub 2004/06/01. doi: 10.1200/JCO.2004.11.069 JCO.2004.11.069 [pii]. PMID: 15169795.
4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51. Epub 2004/06/04. doi: 10.1056/NEJMoa032709 350/23/2343 [pii]. PMID: 15175436.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. Epub 2000/08/16. PMID: 10944126.
6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. Epub 2005/03/25. doi: nrd1691 [pii] doi: 10.1038/nrd1691 PMID: 15789122.
7. Platts JA, Hibbs DE, Hambley TW, Hall MD. Calculation of the Hydrophobicity of Platinum Drugs. J Med Chem. 2000; 44(3):472-4. doi: 10.1021/jm001080k
8. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer. 2000; 82(4):966-72. Epub 2000/03/25. doi: S0007092099910261 [pii] doi: 10.1054/bjoc.1999.1026 PMID: 10732773.
9. Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004; 21(5):891-4. PMID: ISI:000221208200025.
10. Liu JJ, Kim Y, Yan F, Ding Q, Ip V, Jong NN, et al. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem Pharmacol. 2013; 85(2):207-15. doi: http://dx.doi.org/10.1016/j.bcp.2012.10.023 PMID: 23123662
11. Liu JJ, Lu J, McKeage MJ. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr Cancer Drug Targets. 2012; 12(8):962-86. Epub 2012/07/17. doi: CCDT-EPUB-20120712-1 [pii]. PMID: 22794121.
12. Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ. Oxaliplatin transport mediated by OCTN1 and OCTN2 in overexpressing HEK293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 2011; 338(2):537-47. doi: 10.1124/jpet.111.181297 PMID: 21606177
13. Larson CA, Blair BG, Safaei R, Howell SB, editors. The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs. 99th Annual Meeting of the American-Associationfor-Cancer-Research; 2008 Apr 12-16; San Diego, CA: Amer Soc Pharmacology Experimental Therapeutics.
14. Burger H, Zoumaro-Djayoon A, Boersma AWM, Helleman J, Berns E, Mathijssen RHJ, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010; 159(4):898-908. doi: 10.1111/j.1476-5381.2009.00569.x PMID: ISI:000274907800017.
15. Zhang SZ, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006; 66(17):8847-57. doi: 10.1158/0008-5472.can-06-0769 PMID: ISI:000240329400067.
16. Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008; 36(11):2299-306. Epub 2008/08/20. doi: dmd.108.023168 [pii] doi: 10.1124/dmd.108.023168 PMID: 18710896.
17. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006; 319(2):879-86. Epub 2006/08/18. doi: jpet.106.110346 [pii] doi: 10.1124/jpet.106.110346 PMID: 16914559.
18. Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013; 110(27):11199-204. doi: 10.1073/pnas.1305321110 PMID: 23776246
19. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006; 70(4):1390-4. Epub 2006/07/19. doi: mol.106.022624 [pii] doi: 10.1124/mol.106.022624 PMID: 16847145.
20. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004; 10(14):4661-9. Epub 2004/07/23. doi: 10.1158/1078-0432.CCR-04-0137 10/14/4661 [pii]. PMID: 15269138.
21. Li S, Chen Y, Zhang S, More SS, Huang X, Giacomini KM. Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice. Pharm Res. 2011; 28(3):610-25. doi: 10.1007/s11095-010-0312-6 PMID: WOS:000287453300018.
22. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P. ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metabolism Reviews. 2010; 42(3):402-36. doi: 10.3109/03602530903491741 PMID: WOS:000281147900003.
23. Haufroid V. Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition. Curr Drug Targets. 2011; 12(5):631-46. PMID: WOS:000290619400004.
24. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997; 57(24):5475-9. Epub 1998/01/04. PMID: 9407953.
25. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996; 56(18):4124-9. PMID: WOS: A1996VG37000009.
26. Mirakhorli M, Rahman SA, Abdullah S, Vakili M, Rozafzon R, Khoshzaban A. Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. Molecular medicine reports. 2013; 7(2):613-7. doi: 10.3892/mmr.2012.1226 PMID: WOS:000313764300046.
27. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics Journal. 2013; 13(5):403-9. doi: 10.1038/tpj.2012.31 PMID: WOS:000324809100003.
28. Beretta GL, Benedetti V, Cossa G, Assaraf YGA, Bram E, Gatti L, et al. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol. 2010; 79(8):1108-17. doi: 10.1016/j.bcp.2009.12.002 PMID: WOS:000275391400004.
29. Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 2009; 78(11):1366-73. doi: 10.1016/j.bcp.2009.07.006 PMID: ISI:000271069600003.
30. Mohn C, Haecker HG, Hilger RA, Guetschow M, Jaehde U. Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin. Pharmazie. 2013; 68(7):622-7. doi: 10.1691/ph.2013.6523 PMID: WOS:000334260300024.
31. Glavinas H, Mehn D, Jani M, Oosterhuis B, Heredi-Szabo K, Krajcsi P. Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opinion on Drug Metabolism & Toxicology. 2008; 4(6):721-32. doi: 10.1517/17425250802131014 PMID: WOS:000257299400004.
32. Brouwers EEM, Tibben MM, Rosing H, Hillebrand MJX, Joerger M, Schellens JHM, et al. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom. 2006; 41(9):1186-94. doi: 10.1002/jms.1087 PMID: WOS:000240885000007.
33. Screnci D, Galettis P., Baguely B.C., McKeage M.J. Optimisation of an ICP-MS assay for the detection of trace levels of platinum in peripheral nerves. Atomic Spectrometry. 1998; 19:172-5.
34. Ip V, McKeage MJ, Thompson P, Damianovich D, Findlay M, Liu JJ. Platinum-specific detection and quantification of oxaliplatin and Pt(R, R-diaminocyclohexane)Cl-2 in the blood plasma of colorectal cancer patients. Journal of Analytical Atomic Spectrometry. 2008; 23(6):881-4.
35. Fakih S, Munk Vivienne P, Shipman Michelle A, Murdoch Piedad del S, Parkinson John A, Sadler Peter J. Novel Adducts of the Anticancer Drug Oxaliplatin with Glutathione and Redox Reactions with Glutathione Disulfide. European Journal of Inorganic Chemistry. 2003; 2003(6):1206-14. doi: 10.1002/ejic.200390156
36. Jerremalm E, Wallin I, Yachnin J, Ehrsson H. Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate. Eur J Pharm Sci. 2006; 28(4):278-83. doi: 10.1016/j.ejps.2006.03.001 PMID: ISI:000238460100003.
37. van Zanden JJ, de Mul A, Wortelboer HM, Usta M, van Bladeren PJ, Rietjens I, et al. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem Pharmacol. 2005; 69(11):1657-65. doi: 10.1016/j.bcp.2005.03.001 PMID: WOS:000229663500013.
38. van Zanden JJ, Wortelboer HM, Bijlsma S, Punt A, Usta M, van Bladeren PJ, et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol. 2005; 69(4):699-708. doi: 10.1016/j.bcp.2004.11.002 PMID: WOS:000226934100016.
39. Schutte ME, Freidig AP, van de Sandt JJM, Alink GM, Rietjens IMCM, Groten JP. An in vitro and in silico study on the flavonold-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo 4,5-b pyridine (PhIP) through Caco-2 monolayers. Toxicology and Applied Pharmacology. 2006; 217(2):204-15. doi: 10.1016/j.taap.2006.08.005 PMID: WOS:000242287400008.
40. Bible KC, Boerner SA, Kaufmann SH. A one-step method for protein estimation in biological samples: Nitration of tyrosine in nitric acid. Analytical Biochemistry. 1999; 267(1):217-21. doi: 10.1006/abio.1998.2980 PMID: WOS:000078360100026.
41. Munic V, Hlevnjak M, Haber VE. Characterization of rhodamine-123, calcein and 5(6)-carboxy-2′,7′-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur J Pharm Sci. 2011; 43(5):359-69. doi: 10.1016/j.ejps.2011.05.003 PMID: WOS:000293322900001.
42. Heredi-Szabo K, Kis E, Molnar E, Gyorfi A, Krajcsi P. Characterization of 5(6)-carboxy-2,′7′-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4. Journal of Biomolecular Screening. 2008; 13(4):295-301. doi: 10.1177/1087057108316702 PMID: WOS:000254724200004.
43. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993; 53(24):5970-6. Epub 1993/12/15. PMID: 8261411.
44. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999; 55(5):929-37. Epub 1999/04/30. PMID: 10220572.
45. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 1999; 456(2):327-31. Epub 1999/08/24. doi: S0014579399009795 [pii]. PMID: 10456333.
46. Loe DW, Almquist KC, Deeley RG, Cole SPC. Multidrug resistance protein (MRP)-mediated transport of leukotriene C-4 and chemotherapeutic agents in membrane vesicles - Demonstration of glutathione-dependent vincristine transport. J Biol Chem. 1996; 271(16):9675-82. PMID: WOS: A1996UG04400074.
47. Ishikawa T, Aliosman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia-cells - molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem. 1993; 268(27):20116-25. PMID: WOS: A1993LY01900032.
48. Wongwanakul R, Vardhanabhuti N, Siripong P, Jianmongkol S. Effects of rhinacanthin-C on function and expression of drug efflux transporters in Caco-2 cells. Fitoterapia. 2013; 89:80-5. doi: 10.1016/j.fitote.2013.05.019 PMID: WOS:000323856500011.
49. Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics. Drug Metab Dispos. 2012; 40(9):1825-33. doi: 10.1124/dmd.112.046508 PMID: WOS:000308068500021.
50. Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Elferink RPJO, Lagas JS, et al. Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice. J Pharmacol Exp Ther. 2006; 318(1):319-27. doi: 10.1124/jpet.106.101774 PMID: 16611851
51. Gatti L, Beretta GL, Cossa G, Zunino F, Perego P. ABC Transporters as Potential Targets for Modulation of Drug Resistance. Mini-Reviews in Medicinal Chemistry. 2009; 9(9):1102-12. PMID: WOS:000271619400008.